Archive \ Volume.7 2016 Issue 1

Warfarin dose requirement and cytochrome P450 2C9 and Vitamin K epoxide reductase complex subunit 1‑1639 genetic polymorphisms in Thai patients

Burassakorn Subsuphan, Chatchai Chinpaisal, Manat Pongchaidecha, Wibun Phanthabordeekorn, Surawut Watana

Aims: The purposes of this study were to investigate the influence of genetic polymorphisms of cytochrome P450 2C9 (CYP2C9)*3 and Vitamin K epoxide reductase complex subunit 1‑1639 (VKORC1‑1639) G >A and patient’s characteristics on warfarin dose requirement and to establish an equation for predicting the warfarin maintenance dose in Thai patients. Settings and Design: This is an observational, retrospective study in outpatients. Ninety‑one outpatients receiving warfarin at Phaholpolpayuhasena Hospital, Kanchanaburi, were recruited to this study. Subjects and Methods: Whole blood, dose, and demographic data were collected. Blood samples were analyzed for the genetic polymorphism by restriction fragment length polymorphism technique. Statistical Analysis Used: Differences in baseline characteristics among genotypes were evaluated by analysis of variance or Kruskal–Wallis and the Mann–Whitney U‑test or Chi‑square test for parametric and nonparametric variables, respectively. Association between genetic factors and warfarin dose was based on Eta test, whereas associations between warfarin dose and polymorphisms were evaluated using Pearson correlation test. Stepwise regression was used to identify factors contributing to warfarin dose requirement followed by linear regression model to develop a warfarin dosing algorithm. Results: CYP2C9*1*1 (wild type) genotype was found in 90 patients (98.90%), and CYP2C9*1*3 was found in only 1 patient (1.10%). No CYP2C9*3*3 genotype was observed. Polymorphisms of VKORC1‑1639 GG was found in 9 patients (9.89%) while GA and AA genotype were found in 30 patients (32.97%) and in 52 patients (57.14%), respectively. Patients with VKORC1‑1639 AA genotype required statistically and significantly lower, average weekly warfarin dose (19.97 ± 7.61 mg) than GG genotype (37.89 ± 12.20 mg) and GA genotype (29.48 ± 11.50 mg) with the P < 0.05.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.